Serial 79415190
Live / Allowed — Published for opposition (as of 17 Feb 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 07 Jun 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 79415190
- Mark type
- Design / logo
- Filed
- 07 Jun 2024
- Published for opposition
- 17 Feb 2026
- Attorney of record
- Scott J. Major
Goods and services
- Class 005 — Pharmaceuticals: Medical and veterinary preparations for therapeutic purposes, namely, pharmaceutical preparations for treatment of genetic diseases; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceuticals for the delivery of genes to cells, all for medical purposes; chemical preparations for medical purposes, namely, for use in gene therapy and cell therapy; biologic preparations for medical purposes, namely, for use in gene therapy and cell therapy; biologic preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for medical purposes, namely, adeno-associated viral preparations; pharmaceutical preparations in the nature of adeno-associated viral gene therapy preparations; pharmaceutical preparations and substances for the treatment of ocular and otological disorders; biotechnological preparations for the treatment of ocular and otological disorders; pharmaceutical preparations for gene therapy and cell therapy for the treatment of ocular and otological disorders; genetic medicines for the treatment of ocular and otological disorders; biologic preparations for use in the treatment of ophthalmological diseases and disorders; biologic preparations for use in the treatment of blinding and deafness diseases and disorders; biologic preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders; gene therapy preparations for use in the treatment of ophthalmological diseases and disorders; gene therapy preparations for use in the treatment of blinding and deafness diseases and disorders; gene therapy preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders
- Class 010 — Medical apparatus: Medical and surgical apparatus and instruments for use in gene therapy and cell therapy; medical devices for use in gene therapy and cell therapy; apparatus and instruments for the administration of gene therapy products, namely, dosage dispensers for administering medicine; ophthalmic surgery devices and instruments; veterinary apparatus and instruments for use in gene therapy and cell therapy; cannulae; needles for surgical and medical purposes; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof in the nature of dosage dispensers for administering medicine to patients; apparatus and instruments for performing eye surgery; ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic procedures, including surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; medical apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; medical apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products
- Class 040 — Treatment of materials: Custom manufacturing of pharmaceuticals and pharmaceuticals processing; custom manufacturing of biotechnological pharmaceuticals and biopharmaceuticals and processing of biotechnological pharmaceuticals and biopharmaceuticals; custom biomanufacturing for others, namely, manufacturing of viral vectors using biological organisms in the manufacturing process; custom manufacturing of pharmaceuticals for gene therapy; pharmaceutical formulation being custom pharmaceutical manufacturing; information, advice and consultancy services relating to the aforementioned services
- Class 042 — Scientific and technological services: Scientific and technological services and research or design relating thereto, namely, scientific research in the fields of gene therapy and cell therapy; industrial analysis and research services in the fields of gene therapy and cell therapy; biological and medical product research and development; preclinical and clinical research and development in the fields of gene therapy and cell therapy; gene therapy research; genetic engineering, gene editing, namely, the modification of genetic material in a living organism; genetic medicine, gene therapy and genome editing research, development, analytics, clinical trials and consultancy relating thereto; biochemical assay development and performance, namely, monitoring of patients prior and subsequent to gene therapy; diagnostics development and performance, namely, monitoring of patients prior and subsequent to gene therapy; biomarker identification, namely, detection and measurement of biological properties or molecules in the body; manufacturing analytics and manufacturing process design, development and optimisation; scientific research and development services and clinical trials services in relation to pharmaceutical preparations and substances for the treatment of disorders relating to the eye and ear, biotechnological preparations for the treatment of disorders relating to the eye and ear, preparations for gene therapy and cell therapy for the treatment of disorders relating to the eye and ear and genetic medicines for the treatment of disorders relating to the eye and ear; information, advice and consultancy services relating to the aforementioned services
- Class 044 — Medical, beauty and agricultural services: Medical services; medical services in the field of genetic or inherited or non-infectious diseases or disorders; medical services in the field of gene therapy or genetic medicine; medical services in the field of gene therapy for ophthalmological diseases and disorders, blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, renal and kidney disorders, hepatological disorders, or nervous system disorders; medical services, namely, gene and nucleic acid delivery and modification for therapeutic purposes in the fields of gene therapy and cell therapy; medical care and medical analysis services relating to the treatment of patients with gene therapy; medical advisory services in the field of gene therapy; provision of medical information relating to gene therapy and genetic medicine via a website; advisory, consultancy and information services relating to the treatment, relief and/or prevention of eye and ear disease, single gene disorders, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders; information, advice and consultancy services relating to the aforementioned services
Owner
Prosecution history
- 17 Feb 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Feb 2026 — PUBLISHED FOR OPPOSITION
- 11 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Jan 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Jan 2026 — EXAMINER'S AMENDMENT ENTERED
- 23 Jan 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 23 Jan 2026 — EXAMINERS AMENDMENT E-MAILED
- 23 Jan 2026 — EXAMINERS AMENDMENT -WRITTEN
- 18 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 18 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 18 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 30 Nov 2025 — REFUSAL PROCESSED BY IB
- 09 Nov 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 09 Nov 2025 — REFUSAL PROCESSED BY MPU
- 20 Sept 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW